Eva Feldman, M.D., Ph.D., became president of the American Neurological Association on Sept. 27 at the organization’s 136th annual conference in San Diego, Calif.
Feldman, director of the A. Alfred Taubman Medical Research Institute and a professor of neurology at the University of Michigan, will serve a two-year term as head of the 1,800-member ANA, which was established in 1874 by a group of physicians aiming to promote training and research in the field of neurology.
“It’s a great honor to lead a distinguished group of neurologists who share my mission of furthering the research and education that will enable us to find ground-breaking therapies and cures for diseases of the nervous system,” says Feldman, whose faculty appointment at U-M is named for the late Russell N. DeJong, the longtime head of the U-M medical school’s neurology department who also served as ANA president in 1965.
Feldman previously has served as a vice president for the ANA, and she is recent past president of the Peripheral Nerve Society. At U-M, she has an active clinical practice, serves as the research director of the ALS Clinic, and directs the Program for Neurology Research and Discovery, a team of 30 scientists.
Feldman has been listed among the Best Doctors in America for 10 consecutive years.
In her own work, Feldman focuses on amyotrophic lateral sclerosis (ALS – also known as Lou Gehrig’s disease) and the neurological complications of diabetes. She is a leader in applying stem cell research to human disease; most notably she is the Principal Investigator of the first clinical trial of intraspinal transplantation of stem cells in patients with ALS. This Phase 1 trial is currently under way at Emory University in Atlanta, GA. Feldman’s laboratory has begun the work of adapting this therapeutic approach for patients with Alzheimer’s disease.
As director of the Taubman Institute, Feldman spearheads the program which provides unrestricted funding to Taubman Scholars — leading researchers seeking cures for conditions and diseases ranging from diabetes to cancer to obesity. The Institute also supervises the Consortium for Stem Cell Therapies and several other initiatives.